Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia.

Author(s): Goddeau RP Jr, Silverman SB, Sims JR

Affiliation(s): Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.

Publication date & source: 2007, Neurocrit Care., 7(3):217-20.

Publication type: Case Reports

INTRODUCTION: A 38-year-old man with severe head trauma complicated by paroxysmal severe intracranial pressure elevation associated with tachypnea, tachycardia, diaphoresis, and extensor posturing was diagnosed as suffering from paroxysmal autonomic instability with dystonia (PAID). These events were unresponsive to standard medical therapy, which included morphine, fentanyl, labetalol, lorazepam, metoprolol, and clonidine. METHODS: A trial treatment with dexmedetomidine, a central acting alpha2-agonist, to control symptoms of PAID was initiated 12 days after injury. PAID-related events subsided during the 72-h infusion protocol of 0.2-0.7 mcg/kg/h. No further events were noted after termination of the 72-h infusion. CONCLUSIONS: Dexmedetomidine may be a novel pharmacologic agent to aid in abrogating PAID.